ibusinesslines.com
ibusinesslines.com July 22, 2017


Ocular Therapeutix, Inc. (NASDAQ:OCUL) Downgraded by Morgan Stanley

17 July 2017, 08:37 | Kelvin Horton

On 07/13/2017 close, Ocular Therapeutix, Inc. Morgan Stanley lowered shares of Ocular Therapeutix from an "overweight" rating to an "equal weight" rating and set a $16.00 price objective for the company.in a research note on Friday, June 23rd. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company's stock worth $103,000 after buying an additional 844 shares during the last quarter.

A number of brokerages have recently weighed in on OCUL. The other 3, though not evenly; between analysts who think you should buy Ocular Therapeutix, Inc. versus those who think you should sell it. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $27.00 on company shares. The firm has "Overweight" rating by Cantor Fitzgerald given on Friday, February 10. They now have a Dollars 21 price target on the stock. The stock experienced -4.88% slump, arriving at $6.33 on Jul. 14, 2017. In contrast, the average volume was 1.37 million shares. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -30.31% where SMA50 and SMA200 are -32.26% and -22% respectively. Ocular Therapeutix has a one year low of $4.04 and a one year high of $11.91. The stock's market capitalization is $178.52 million.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Friday, May 5th. The company maintains price to book ratio of 2.15 vs.an industry average at 1.27. It has a return on equity (ROE) of -80.20%. The firm had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.51 million. (OCUL) is -0.58 while the analysts predicted the EPS of the stock to be -0.48 suggesting the company fell short of the analysts' expectations. On average, equities analysts expect that Ocular Therapeutix will post ($2.25) EPS for the current fiscal year. The correct version of this article can be viewed at https://www.com-unik.info/2017/07/17/fy2017-eps-estimates-for-ocular-therapeutix-inc-lifted-by-cantor-fitzgerald-nasdaqocul.html. Cantor Fitzgerald now has a "Overweight" rating and a $21.00 target price on the stock. If you are reading this news story on another website, it was stolen and reposted in violation of global trademark & copyright laws. About shares traded. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 9.50% since July 17, 2016 and is downtrending.

Institutional investors have recently added to or reduced their stakes in the company.


ILLEGAL ACTIVITY WARNING: "49,024 Shares in Ocular Therapeutix, Inc".

A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. Berson & Corrado Investment Advisors LLC increased its stake in Ocular Therapeutix by 5.8% in the first quarter. Columbus Circle Investors boosted its stake in Ocular Therapeutix by 131.4% in the first quarter. Deltec Asset Management LLC now owns 399,200 shares of the biopharmaceutical company's stock worth $3,705,000 after buying an additional 284,200 shares during the period. Finally, Trexquant Investment LP bought a new position in shares of Ocular Therapeutix during the fourth quarter valued at about $181,000.

Institutional investors now hold around $122 million or 63.9% in OCUL stock.

Taking a look back at some historical performance numbers for Ocular Therapeutix, Inc. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.



Other News

Trending Now

Is Buying Hornbeck Offshore Services, Inc. (HOS) Here a Winning Strategy?
California State Teachers Retirement Systems invested 0.2% of its portfolio in Danaher Corporation (NYSE:DHR). (NYSE:HOS). Morgan Stanley holds 0% or 176,122 shares. 312,219 were reported by Metropolitan Life Insurance Co New York.

Swiss National Bank Has $1805000 Position in Dominion Diamond Corporation (DDC)
The basic materials company reported $0.09 EPS for the quarter, beating the Zacks' consensus estimate of $0.05 by $0.04. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover DDC having a buy-equivalent rating.

The Fairmount Santrol Holdings Target of Unusually Large Options Trading (FMSA)
The stock of Fairmount Santrol Holdings Inc (NYSE:FMSA) earned "Sector Outperform" rating by Howard Weil on Monday, December 14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link .

Ryan Phillippe hospitalized for leg injury
While the Shooter star doesn't seem to be in the happiest of moods, he gives the camera a solid thumbs-up with his right hand. He said in an interview with Collider published in November that he insisted on doing all of his own stunts for the show.

Apple embraces zombies and elves for new emojis in iOS 11
The new emoji are technically a set of emoji that are launching as part of Unicode 10.0, the standard set for emoticons. As the world marks World Emoji Day , Apple has revealed its newest ones that focus on the weird and wonderful.

Trump warns he won't visit United Kingdom until he gets 'better reception'
As The Sun's source told the paper, Britain is not North Korea and can not order the media to give Trump positive coverage. According to The Sun , he added: 'When I know I'm going to get a better reception, I'll come and not before'.

Kylie Minogue rekindles romance with ex Olivier Martinez on secret Hollywood date
Olivier is recently single after finalising his divorce form Hollywood A-lister Halle Berry , 50, in December. They were very tactile throughout the meal and kissed several times, " said a source to the magazine.